Human medicines European public assessment report (EPAR): Zonisamide Viatris (previously Zonisamide Mylan), zonisamide, Date of authorisation: 31/03/2016, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Zynlonta, loncastuximab tesirine, Date of authorisation: 20/12/2022, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Abrysvo, respiratory syncytial virus vaccine (bivalent, recombinant), Date of authorisation: 23/08/2023, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Xolremdi, mavorixafor, Date of authorisation: 27/04/2026, Revision: 4, Status: Authorised

International collaboration on GMP inspections

Report on the International Active Pharmaceutical Ingredient Inspection Programme 2017 – 2024

Human medicines European public assessment report (EPAR): Aybintio, bevacizumab, Date of authorisation: 19/08/2020, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Vyloy, zolbetuximab, Date of authorisation: 19/09/2024, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Repaglinide Accord, repaglinide, Date of authorisation: 22/12/2011, Revision: 8, Status: Withdrawn

Human medicines European public assessment report (EPAR): Bilprevda, denosumab, Date of authorisation: 17/09/2025, Revision: 5, Status: Authorised